PART I . Overview We are a clinical-stage biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases. We believe immunotherapies are one of the forward pillars of medicine, and our mission is to advance humanity by engineering immunotherapies that are safer, more effective and more broadly accessible. Although Chimeric Antigen Receptor T-cells (CAR-Ts) have shown benefits to date, they have primarily been constraine...
Q2 FY2026 — expected 2026-08-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-076876 | EDGAR | 116K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-029150 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0000950170-24-022048 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0000950170-23-010610 | EDGAR | — |
| 2022-03-24 | 2021-12-31 | 0000950170-22-004573 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001193125-25-266932 | EDGAR | 63K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105064 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-067100 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123442 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094120 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-057007 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062930 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042402 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018782 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-025099 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017455 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009732 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-23 | 0001193125-26-063955 | EDGAR | 52K words |
| 2025-12-08 | 0001193125-25-311276 | EDGAR | — |
| 2025-11-05 | 0001193125-25-266866 | EDGAR | — |
| 2025-08-07 | 0000950170-25-105015 | EDGAR | — |
| 2025-05-28 | 0001193125-25-129522 | EDGAR | — |
| 2025-05-14 | 0001193125-25-119506 | EDGAR | — |
| 2025-05-08 | 0001193125-25-116023 | EDGAR | — |
| 2025-03-20 | 0001193125-25-058978 | EDGAR | — |
| 2025-02-27 | 0001193125-25-039316 | EDGAR | — |
| 2024-12-12 | 0001193125-24-275844 | EDGAR | — |
73 total filings indexed. 46 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001786205 |
| Ticker | ACLX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report